Literature DB >> 25522809

Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity.

Isabelle Archambeaud1, Hélène Auble1, Pierre Nahon2, Lucie Planche3, Guillaume Fallot4, Roger Faroux5, Jérôme Gournay1, Didier Samuel4, Sebastien Kury6, Cyrille Féray7.   

Abstract

BACKGROUND & AIMS: In patients with cirrhosis, the risk of hepatocellular carcinoma (HCC) depends upon age, gender and the etiology of liver disease. Few studies are available in Caucasian patients with alcoholic or metabolic cirrhosis without viral hepatitis.
METHODS: Cross-sectional clinical data from 905 HCV- and HBV-negative Caucasian patients with alcoholic or metabolic cirrhosis were prospectively collected in four French centres. The risk factors for HCC were identified by logistic regression analysis in the whole population and in a nested case-control study.
RESULTS: The etiology of cirrhosis was alcoholic (48%), metabolic (7%) or mixed (45%). Patients were predominantly male (80%), mean age 62 years old and 31% had HCC. Mean body mass index (BMI) was 27 ± 5 and 30% were obese at inclusion. The maximum BMI reached throughout life was 31 ± 6 and 63% had been obese. Ninety percent of the population had daily alcohol consumption, 73% were smokers. Hepatocellular carcinoma was independently related to male gender (P < 0.0001), older age (P < 0.0001), past obesity (P = 0.007), diabetes (P = 0.037), abnormal levels of transaminases (P < 0.0001) and tobacco consumption (P = 0.007). The case-control study (200 HCC cases matched with 400 non-HCC cases for gender, age and Child-Pugh score) confirmed past obesity, tobacco and abnormal levels of transaminases.
CONCLUSIONS: Beside diabetes, male gender and age, a past history of obesity, but not an existing overweight, as well as exposure to tobacco and elevated transaminases were three risk factors which could improve the strategy for HCC screening in Caucasian cirrhotic patients without hepatitis B or C.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Caucasian; cirrhosis; hepatocellular carcinoma; obesity

Mesh:

Year:  2015        PMID: 25522809     DOI: 10.1111/liv.12767

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

2.  Risk factors for HCC in contemporary cohorts of patients with cirrhosis.

Authors:  Fasiha Kanwal; Saira Khaderi; Amit G Singal; Jorge A Marrero; Nicole Loo; Sumeet K Asrani; Christopher I Amos; Aaron P Thrift; Xiangjun Gu; Michelle Luster; Abeer Al-Sarraj; Jing Ning; Hashem B El-Serag
Journal:  Hepatology       Date:  2022-03-01       Impact factor: 17.298

3.  Microarray analysis for the identification of specific proteins and functional modules involved in the process of hepatocellular carcinoma originating from cirrhotic liver.

Authors:  Wufeng Fan; Guangming Ye
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

4.  Intra-aortic balloon pump-assisted major hepatectomy in a case with coronary disease.

Authors:  Kazuo Okadome; Hiromitsu Hayashi; Takaaki Higashi; Hideaki Takeyama; Keita Sakamoto; Hideyuki Kuroki; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Surg Case Rep       Date:  2015-11-02

5.  Loss-of-function mutations in Zn-finger DNA-binding domain of HNF4A cause aberrant transcriptional regulation in liver cancer.

Authors:  Hiroaki Taniguchi; Akihiro Fujimoto; Hidetoshi Kono; Mayuko Furuta; Masashi Fujita; Hidewaki Nakagawa
Journal:  Oncotarget       Date:  2018-05-25

6.  Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types.

Authors:  Chenyue Zhang; Chenxing Zhang; Qingliang Wang; Zhenxiang Li; Jiamao Lin; Haiyong Wang
Journal:  JAMA Netw Open       Date:  2020-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.